PharmNovo Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.05M

  • Investors
  • 9

PharmNovo General Information

Description

Developer of nerve pain drugs and therapies intended to discover safe and effective drugs to make lives better. The company's research combines smart chemistry and bioscience to discover new medicines based on non-addictive opioids to treat diseases of the nervous system, enabling people to access chronic pain relief to improve their quality of life.

Contact Information

Website
www.pharmnovo.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Medicon Village AB
  • Scheeletorget 1
  • 223 81 Lund
  • Sweden
+46
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Medicon Village AB
  • Scheeletorget 1
  • 223 81 Lund
  • Sweden
+46

PharmNovo Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PharmNovo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC 10-Jul-2026 $4.05M Completed Clinical Trials - Phase 2
11. Later Stage VC 22-Jan-2024 Cancelled Clinical Trials - Phase 1
10. Grant 13-Mar-2024 Completed Clinical Trials - Phase 1
9. Later Stage VC 01-Nov-2023 Completed Clinical Trials - Phase 1
8. Later Stage VC 03-Jun-2022 Completed Clinical Trials - Phase 1
7. Later Stage VC 03-Oct-2020 Completed Clinical Trials - Phase 1
6. Angel (individual) 01-Jan-2018 Completed Startup
5. Grant Completed Startup
4. Angel (individual) 01-Jan-2015 $156K $484K Completed Startup
3. Angel (individual) 01-Jan-2014 $328K $328K Completed Startup
To view PharmNovo’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

PharmNovo Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

PharmNovo Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026161009-A1 Delta opioid receptor agonists for use in the treatment of pain Pending 21-Jan-2025
EP-4182312-B1 Polymorph of a hydrochloride salt of pn6047 Active 17-Jul-2020
AU-2021309364-A1 Polymorphs of a hydrochloride salt of pn6047 Pending 17-Jul-2020
AU-2021309364-A8 Polymorphs of a hydrochloride salt of pn6047 Pending 17-Jul-2020
CA-3185973-A1 Polymorphs of a hydrochloride salt of pn6047 Pending 17-Jul-2020 C07D417/06
To view PharmNovo’s complete patent history, request access »

PharmNovo Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PharmNovo Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
European Innovation Council Accelerator/Incubator Minority
Mac Equity Venture Capital Minority
Polynom Investment Venture Capital Minority
UCEA Capital Partners Family Office Minority
Jinderman & Partners Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

PharmNovo Investments (1)

PharmNovo’s most recent deal was a Seed Round with Messium. The deal was made on 01-Nov-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Messium 01-Nov-2023 Seed Round Media and Information Services (B2B)
To view PharmNovo’s complete investments history, request access »

Ready to get started?

Request a free trial

PharmNovo FAQs

  • When was PharmNovo founded?

    PharmNovo was founded in 2008.

  • Where is PharmNovo headquartered?

    PharmNovo is headquartered in Lund, Sweden.

  • What is the size of PharmNovo?

    PharmNovo has 10 total employees.

  • What industry is PharmNovo in?

    PharmNovo’s primary industry is Drug Discovery.

  • Is PharmNovo a private or public company?

    PharmNovo is a Private company.

  • What is PharmNovo’s current revenue?

    The current revenue for PharmNovo is .

  • How much funding has PharmNovo raised over time?

    PharmNovo has raised $16M.

  • Who are PharmNovo’s investors?

    European Innovation Council, Mac Equity, Polynom Investment, UCEA Capital Partners, and Jinderman & Partners are 5 of 9 investors who have invested in PharmNovo.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process